SEC For	m 4																			
FORM 4			UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549														OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										HIP	Estim	Numbe nated av s per res	erage burde	3235-0287 n 0.5	
1. Name and Address of Reporting Person* Hoerter Steven L.						2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Deciphera Pharmaceuticals, Inc.</u> [ DCPH ]									elationship of ck all applica Director	able)	ıg Pers	10% O	vner	
(Last)(First)(Middle)C/O DECIPHERA PHARMACEUTICALS, INC.200 SMITH STREET						3. Date of Earliest Transaction (Month/Day/Year) 01/18/2022									below)	give title Presiden	ive title Other (s below) resident and CEO			
(Street) WALTHAM MA 02451					4. If Amendment, Date of Original Filed (Month/Day/Year)									Line)	<ul> <li>B. Individual or Joint/Group Filing (Check Applicable Line)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting Person</li> </ul>				'n	
(City) (State) (Zip)																				
		Та	ble I - Nor	-Deriva	ativ	/e Se	ecur	ities Ac	quired, D	Dis	posed c	of, or B	ene	ficially	Owned					
1. Title of Security (Instr. 3)       2. Trans. Date (Month/I)				Execution Date			Code (Instr.				(A) or 3, 4 and 5	) or 4 and 5) 5. Amount Securities Beneficial Owned Fo Reported		Form ly (D) o		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
						Code	v	Amount	(A) (D)	or	Price	Transaction (Instr. 3 and				(11311. 4)				
			Table II - I (						uired, Di s, options						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	Transaction Code (Instr.		Deri Sec Acq or D of (E	umber of vative urities uired (A) visposed D) (Instr. and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Numbo derivativ Securitie Beneficia Owned Followin Reported	re es ally g d	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				Co	de	v	(A)		Date Exercisable		Expiration Date	Title	OI N	mount r umber f Shares		Transaction(s) (Instr. 4)				
Stock Option (Right to Buy)	\$8.27	01/18/2022		A				415,000	(1)	0	1/17/2032	Common Stock	<sup>n</sup> 4	15,000	\$0.00	415,0	000	D		

Explanation of Responses:

1. This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four (4) years, beginning on February 18, 2022.

**Remarks:** 

/s/ Thomas P. Kelly, Attorney-01/20/2022 in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.